PMID: 19928542Nov 26, 2009Paper

Clinical assessment of the effect of switch from immediate-release to extended-release methylphenidate in 181 patients with isolated attention deficit/hyperactivity disorder (AD/HD) or AD/HD associated with pervasive developmental disorder

No to hattatsu. Brain and development
Michiko Sugama, Asayo Ishizaki

Abstract

We switched medication from conventional immediate-release preparations of methylphenidate to extended-release tablets (an osmotic release oral system) in 165 of 181 cases with attention deficit/hyperactivity disorder (AD/HD), in accordance with the revised indications for these tablets. We investigated the types of developmental disorders, doses of the drug, efficacy, adverse effects, concomitant medication, other relevant problems, and so on, prior to switching the medications. The most common types of developmental disorders were AD/HD with symptoms of pervasive developmental disorder (PDD) and PDD with symptoms of AD/HD. The efficacy evaluation revealed that the extended release tablets had efficacy equivalent to or greater than that of the immediate release preparation. The efficacy rate was 82.7% in our patients. However, cases with difficulty ingesting the tablets, requiring small doses, and those over 18 years of age still seen in the pediatrics department, remained as problematic issues which require further consideration.

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Autism

Autism spectrum disorder is associated with challenges with social skills, repetitive behaviors, and often accompanied by sensory sensitivities and medical issues. Here is the latest research on autism.